The purpose of this program is to provide patients with PDP access to pimavanserin until the product receives marketing approval from the FDA and is commercially available.
Study Type
EXPANDED_ACCESS
Pimavanserin tartrate 40 mg, tablet, taken as two 20 mg tablets, once daily by mouth
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.